IDEAYA Biosciences, Inc. Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount
IDEAYA Biosciences, Inc. (IDYA) had Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount of $158.30 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions · last filed 2026-08-04
- 2026-06-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $158.30M.
- 2026-03-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $161.60M.
- 2025-12-31: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $96.20M.
- 2025-09-30: Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount $108.40M.
| Period end | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount | Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount as first filed |
|---|---|---|
| 2026-06-30 | $158.30M 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $161.60M 10-Q · filed 2026-05-05 | |
| 2025-12-31 | $96.20M 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $108.40M 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $118.80M 10-Q · filed 2025-08-05 | |
| 2025-03-31 | $96.20M 10-Q · filed 2026-05-05 | $115.70M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $90.20M 10-K · filed 2026-02-17 | |
| 2024-09-30 | $96.90M 10-Q · filed 2024-11-04 | |
| 2024-06-30 | $105.20M 10-Q · filed 2024-08-06 | |
| 2024-03-31 | $105.80M 10-Q · filed 2024-05-07 | |
| 2023-12-31 | $41.10M 10-K · filed 2025-02-18 | |
| 2023-09-30 | $46.80M 10-Q · filed 2023-11-07 | |
| 2023-06-30 | $50.50M 10-Q · filed 2023-08-10 | |
| 2023-03-31 | $47.90M 10-Q · filed 2023-05-09 | |
| 2022-12-31 | $28.00M 10-K · filed 2024-02-20 | |
| 2022-09-30 | $28.00M 10-Q · filed 2022-11-08 | |
| 2022-06-30 | $30.10M 10-Q · filed 2022-08-15 | |
| 2022-03-31 | $31.90M 10-Q · filed 2022-05-10 | |
| 2021-12-31 | $22.20M 10-Q · filed 2022-11-08 | |
| 2021-09-30 | $21.50M 10-Q · filed 2021-11-15 | |
| 2021-06-30 | $21.40M 10-Q · filed 2021-08-10 | |
| 2021-03-31 | $21.80M 10-Q · filed 2021-05-10 | |
| 2020-12-31 | $8.50M 10-Q · filed 2021-11-15 | |
| 2020-09-30 | $9.00M 10-Q · filed 2020-11-12 | |
| 2020-06-30 | $8.30M 10-Q · filed 2020-08-12 | |
| 2020-03-31 | $8.70M 10-Q · filed 2020-05-12 | |
| 2019-12-31 | $5.90M 10-Q · filed 2020-11-12 | |
| 2019-09-30 | $6.20M 10-Q · filed 2019-11-13 | |
| 2019-06-30 | $6.60M 10-Q · filed 2019-08-12 | |
| 2018-12-31 | $4.20M 10-Q · filed 2019-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |